Thyroid Cancer and NVP-BEZ235 43. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472–1487. 44. Liu Z, Wu G, Xing M (2009) Genetic alterations in the phosphoinositide 3- kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69: 7311–7319. 45. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K- dependent feedback loop in human cancer. J Clin Invest 118: 3065–3074. 46. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW (2011) Synergistic action of a RAF inhibitor and a dual PI-3 Kinase/mTOR inhibitor in thyroid cancer. Clin Cancer Res 17: 6482–6489. 47. Liu D, Xing J, Trink B, Xing M (2010) BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic- potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 127: 2965–2973. 48. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW (2009) Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 94: 4107– 4112. PLOS ONE | www.plosone.org 12 October 2012 | Volume 7 | Issue 10 | e46726